Innate immunity is the first line of defense in the body's immune system, providing rapid and nonspecific protection against a wide range of pathogens. It is an evolutionarily ancient form of immunity that acts immediately upon encountering foreign invaders. Key components of innate immunity include physical barriers like the skin and mucous membranes, as well as cellular components such as phagocytes (like neutrophils and macrophages) and natural killer (NK) cells. These cells are equipped to recognize and eliminate pathogens without the need for prior exposure. Innate immunity also involves the activation of the complement system, a group of proteins that enhance the immune response by promoting inflammation, phagocytosis, and the destruction of pathogens. While innate immunity provides rapid protection, it lacks the specificity and memory characteristic of adaptive immunity. Innate and adaptive immunity work collaboratively, with innate responses initiating the defense against pathogens, and adaptive responses developing over time for more precise and targeted protection. Dysregulation of innate immunity can lead to various diseases, including inflammatory conditions and autoimmune disorders. Understanding the complexities of innate immunity is crucial for developing strategies to modulate the immune system and combat infections and diseases effectively.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States